Technical Analysis for GNCA - Genocea Biosciences, Inc.

Grade Last Price % Change Price Change
grade C 0.59 0.85% 0.01
GNCA closed up 0.85 percent on Friday, January 18, 2019, on 15 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Up
See historical GNCA trend table...

Date Alert Name Type % Chg
Jan 18 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Jan 18 Narrow Range Bar Range Contraction 0.00%
Jan 18 NR7 Range Contraction 0.00%
Jan 18 Inside Day Range Contraction 0.00%
Jan 18 Wide Bands Range Expansion 0.00%
Jan 18 Overbought Stochastic Strength 0.00%
Jan 17 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.85%
Jan 17 Wide Bands Range Expansion 0.85%
Jan 17 Overbought Stochastic Strength 0.85%
Jan 16 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -3.28%

Older signals for GNCA ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Genocea Biosciences, Inc., a clinical stage biotechnology company, discovers and develops novel vaccines to treat infectious diseases. The company, through its proprietary discovery platform, AnTigen Lead Acquisition System (ATLAS), designs vaccines that stimulate T cell immunity. The company primarily develops GEN-003, a candidate therapeutic vaccine or immunotherapy, which is in Phase 1/2a trial to treat herpes simplex virus-2 or HSV-2 infections; and GEN-004, a T cell vaccine candidate that is in Phase 1 trial to prevent infections caused by pneumococcus. It also develops earlier-stage programs for chlamydia, HSV-2 prophylaxis, and malaria. The company, formerly known as Genocea, Inc., was founded in 2006 and is headquartered in Cambridge, Massachusetts.
Is GNCA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 1.25
52 Week Low 0.28
Average Volume 292,702
200-Day Moving Average 0.7238
50-Day Moving Average 0.5509
20-Day Moving Average 0.4747
10-Day Moving Average 0.5842
Average True Range 0.061
ADX 29.59
+DI 25.6209
-DI 12.1134
Chandelier Exit (Long, 3 ATRs ) 0.477
Chandelier Exit (Short, 3 ATRs ) 0.463
Upper Bollinger Band 0.7102
Lower Bollinger Band 0.2392
Percent B (%b) 0.74
BandWidth 99.22056
MACD Line 0.0246
MACD Signal Line 0.0032
MACD Histogram 0.0214
Fundamentals Value
Market Cap 16.89 Million
Num Shares 28.6 Million
EPS -2.04
Price-to-Earnings (P/E) Ratio -0.29
Price-to-Sales 0.00
Price-to-Book 1.80
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.62
Resistance 3 (R3) 0.62 0.62 0.62
Resistance 2 (R2) 0.62 0.61 0.62 0.61
Resistance 1 (R1) 0.60 0.60 0.60 0.60 0.61
Pivot Point 0.60 0.60 0.60 0.60 0.60
Support 1 (S1) 0.58 0.59 0.58 0.58 0.57
Support 2 (S2) 0.58 0.58 0.58 0.57
Support 3 (S3) 0.56 0.58 0.57
Support 4 (S4) 0.56